Immigration and Customs Enforcement (ICE) Medical Supply Support Services

The primary mission of the U.S. Department of Homeland Security (DHS) is to lead the unified national effort to secure the country and preserve our freedoms. While the Department was created to secure our country against those who seek to disrupt the American way of life, our charter also includes preparation for and response to all hazards and disasters. ICE is responsible for the protection of the security of the American people and homeland by vigilantly enforcing the nation’s immigration and customs laws.

This requirement encompasses nationwide, pre-employment and post-employment medical, psychological, fitness, and drug testing services for ICE personnel. Pre-employment medical services include selectee medical, fitness, and drug testing in accordance with U.S. Department of Health and Human Services (HHS) regulations. Post-employment medical services include support for the Drug Free Federal Workplace Program, independent medical examinations, reviews of medical documents, and ancillary testing for ICE employees.

Potential locations where services will be delivered include all 50 U.S. states, plus locations in Puerto Rico, the Virgin Islands, the Mariana Islands to include Guam, and possibly any location throughout the seven continents. Requests for pre-employment testing will originate from the ICE Office of Human Capital (OHC) Human Resources Operations Center (HROC) Dallas Pre-Employment Clearance (PEC) Unit.

For ICE employees, examinations and testing will originate from the ICE OHC Fitness for Duty Coordinator (FFDC) or Drug Program Coordinator (DPC). A capability to accept notification of the need for drug or alcohol testing in reasonable-suspicion cases must be available via telephone 24-hours a day, 7 calendar days a week. The anticipated source selection is estimated to result in one contract with a base year plus four one-year options, for a total of five years if all options are exercised. The contract is planned to be Firm Fixed Price, with a performance start date of 1 July 2024.